Cubist Systematic Strategies LLC Grows Position in Y-mAbs Therapeutics, Inc. $YMAB

Key Points

• Cubist Systematic Strategies LLC increased its stake in Y-mAbs Therapeutics by 223.9%, owning 155,522 shares worth $689,000 as of its latest SEC filing.
• Y-mAbs Therapeutics reported a quarterly loss of ($0.07) EPS, exceeding analyst expectations, with revenue of $19.52 million despite a net margin of -26.03%.
• Several analysts have downgraded Y-mAbs stock ratings to "hold" and set a price target of $8.60, with an average target price of $9.62 across analysts.

Cubist Systematic Strategies LLC grew its position in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB - Free Report) by 223.9% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 155,522 shares of the company's stock after acquiring an additional 107,511 shares during the quarter. Cubist Systematic Strategies LLC owned about 0.34% of Y-mAbs Therapeutics worth $689,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Stonepine Capital Management LLC bought a new stake in Y-mAbs Therapeutics during the 1st quarter valued at about $581,000. Jump Financial LLC lifted its holdings in Y-mAbs Therapeutics by 14.1% during the 1st quarter. Jump Financial LLC now owns 38,079 shares of the company's stock valued at $169,000 after buying an additional 4,699 shares in the last quarter. AlphaQuest LLC lifted its holdings in Y-mAbs Therapeutics by 43.4% during the 1st quarter. AlphaQuest LLC now owns 38,925 shares of the company's stock valued at $172,000 after buying an additional 11,790 shares in the last quarter. EntryPoint Capital LLC bought a new stake in Y-mAbs Therapeutics during the 1st quarter valued at about $56,000. Finally, Wellington Management Group LLP lifted its holdings in Y-mAbs Therapeutics by 53.1% during the 1st quarter. Wellington Management Group LLP now owns 204,052 shares of the company's stock valued at $904,000 after buying an additional 70,789 shares in the last quarter. Institutional investors own 70.85% of the company's stock.

Y-mAbs Therapeutics Price Performance

Shares of Y-mAbs Therapeutics stock remained flat at $8.59 on Friday. 522,855 shares of the stock were exchanged, compared to its average volume of 865,316. The firm's 50-day moving average price is $6.84 and its 200 day moving average price is $5.38. Y-mAbs Therapeutics, Inc. has a 52-week low of $3.55 and a 52-week high of $16.11.

Y-mAbs Therapeutics (NASDAQ:YMAB - Get Free Report) last issued its quarterly earnings data on Friday, August 8th. The company reported ($0.07) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.27) by $0.20. Y-mAbs Therapeutics had a negative net margin of 26.03% and a negative return on equity of 24.60%. The firm had revenue of $19.52 million for the quarter, compared to the consensus estimate of $18.40 million. As a group, equities research analysts forecast that Y-mAbs Therapeutics, Inc. will post -0.65 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages recently weighed in on YMAB. Oppenheimer lowered shares of Y-mAbs Therapeutics from an "outperform" rating to a "market perform" rating in a report on Tuesday, August 5th. Brookline Capital Management lowered shares of Y-mAbs Therapeutics from a "strong-buy" rating to a "hold" rating in a report on Tuesday, August 5th. Canaccord Genuity Group lowered shares of Y-mAbs Therapeutics from a "strong-buy" rating to a "hold" rating and reduced their price target for the company from $26.00 to $8.60 in a report on Tuesday, August 5th. Truist Financial set a $8.60 price target on shares of Y-mAbs Therapeutics in a report on Tuesday, August 5th. Finally, Jones Trading lowered shares of Y-mAbs Therapeutics from a "strong-buy" rating to a "hold" rating in a report on Tuesday, August 5th. Eight research analysts have rated the stock with a Hold rating and two have assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Reduce" and an average target price of $9.62.

Y-mAbs Therapeutics Profile

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.